![]() Mangiarini L, Sathasivam K, Mahal A et al (1997) Instability of highly expanded CAG repeats in mice transgenic for the Huntington’s disease mutation. Neueder A, Landles C, Ghosh R et al (2017) The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington’s disease patients. Sathasivam K, Neueder A, Gipson TA et al (2013) Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Southwell AL, Skotte NH, Villanueva EB et al (2017) A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. Southwell AL, Warby SC, Carroll JB et al (2013) A fully humanized transgenic mouse model of Huntington disease. Van Raamsdonk JM, Metzler M, Slow E et al (2007) Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Gray M, Shirasaki DI, Cepeda C et al (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis i n BACHD mice. Laforet GA, Sapp E, Chase K et al (2001) Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington’s disease. Schilling G, Becher MW, Sharp AH et al (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. ![]() Morton AJ, Glynn D, Leavens W et al (2009) Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Menalled L, El-Khodor BF, Patry M et al (2009) Systematic behavioral evaluation of Huntington’s disease transgenic and knock-in mouse models. Mangiarini L, Sathasivam K, Seller M et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 90:537–548ĭragatsis I, Goldowitz D, Del Mar N et al (2009) CAG repeat lengths > or = 335 attenuate the phenotype in the R6/2 Huntington’s disease transgenic mouse. J Neurophysiol 107:677–691ĭavies SW, Turmaine M, Cozens BA et al (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. J Neurosci 19:3248–3257Ĭummings DM, Alaghband Y, Hickey MA et al (2012) A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington’s disease. Brain Res Bull 88:94–103Ĭarter RJ, Lione LA, Humby T et al (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington’s disease mutation. Brain Res Bull 88:104–112īrooks SP, Janghra N, Workman VL et al (2012) Longitudinal analysis of the behavioural phenotype in R6/1 (C57BL/6J) Huntington’s disease transgenic mice. Cell 72:971–983īayram-Weston Z, Jones L, Dunnett SB, Brooks SP (2012) Light and electron microscopic characterization of the evolution of cellular pathology in the R6/1 Huntington’s disease transgenic mice. ![]() Macdonald ME, Ambrose CM, Duyao MP et al (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntingtons-disease chromosomes. Vonsattel J-P, Myers RH, Stevens TJ et al (1985) Neuropathological classification of Huntington’s disease. Bates G, Tabrizi S, Jones L (2014) Huntington’s disease, vol 64.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |